All Blogs

May 12, 2025

The pharmaceutical industry is witnessing a seismic shift, fueled by the meteoric rise of GLP-1 agonist molecules. Once a niche class of diabetes drugs, GLP-1 agonists have become the cornerstone of a global race to conquer obesity, a disease that has more than doubled in prevalence since 1990 and now affects over ...

Aug 08, 2024

MIMEDX Announced the Launch of HELIOGENTM Fibrillar Collagen Matrix  On July 31, 2024, MiMedx Group, Inc. launched HELIOGEN™ Fibrillar Collagen Matrix, a particulate xenograft product designed to treat complex wounds, especially in surgical environments. HELIOGEN is a shelf-stable product that contains Type...

Aug 07, 2024

Adenovirus-associated oncolytic virus therapies represent a promising approach to cancer treatment by harnessing the inherent ability of viruses to selectively infect and destroy cancer cells. These therapies utilize genetically modified adenoviruses, which are engineered to target and replicate specifically within...

Aug 06, 2024

Adaptimmune’s TECELRA Becomes First FDA-Approved Engineered Cell Therapy for Solid Tumors Adaptimmune Therapeutics announced that the FDA has approved (afamitresgene autoleucel), which will be marketed under the brand name TECELRA, for the treatment of unresectable or metastatic synovial sarcoma. This marks the ...

Aug 05, 2024

Despite significant progress in multiple myeloma treatment with a range of biological drugs and their combinations—such as IMiDs (BMS REVLIMID, POMALYST/IMNOVID), anti-CD38 monoclonal antibody drugs (DARZALEX, SARCLISA), the anti-SLAM7 monoclonal antibody (AbbVie and BMS multiple myeloma drug EMPLICITI), and new pr...

Mar 12, 2025

With the growing global health concern regarding obesity, Novo’s WEGOVY (semaglutide) has emerged as a leading solution in the weight loss treatment market. WEGOVY is a GLP-1 receptor agonist used alongside a low-calorie diet and increased physical activity. This obesity medication is administered as a weekly subcu...

Aug 01, 2024

FDA Approved Stryker’s Spine Guidance 5 Software Featuring Copilot On July 30, 2024, Stryker, a global leader in medical technologies, announced that its Q Guidance System with Spine Guidance 5 Software featuring Copilot received 510(k) clearance from the U.S. Food and Drug Administration. This first-to-market t...

Jul 31, 2024

As cancer continues to be a leading cause of mortality worldwide, there is a growing urgency to develop innovative oncolytic virus therapies that can effectively target and eradicate cancer cells. With its unique ability to selectively infect and replicate within tumor cells, oncolytic virus therapy has emerged as ...

Jul 30, 2024

The FDA Advisory Committee Considers the AEGEAN Phase III Trial Data in their Review of IMFINZI for Treating Resectable NSCLC The FDA's Oncologic Drugs Advisory Committee (ODAC) acknowledged that AstraZeneca’s IMFINZI (durvalumab) achieved the primary endpoint of event-free survival (EFS) in resectable non-small...

Jul 29, 2024

With an estimated 1 million patients affected in the US, thyroid eye disease is a burden for some disorders which become sight-threatening in upto 5% of the cases. Until today, only one thyroid eye disease treatment drug for adults has been approved by the FDA.  Developed by Horizon Therapeutics (now acquir...